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Abstract 29 30
Von Hippel-Landau (VHL) protein is a potent tumor suppressor regulating 31 numerous pathways that drive cancer, but mutations in VHL are restricted to 32 limited subsets of malignancies. Here we identified a novel mechanism for VHL 33 suppression in tumors that do not have inactivating mutations. Using 34 developmental processes to uncover new pathways contributing to tumorigenesis, 35
we found that Daam2 promotes glioma formation. Protein expression screening 36 identified an inverse correlation between Daam2 and VHL expression across a 37 host of cancers, including glioma. These in silico insights guided corroborating 38 functional studies, which revealed that Daam2 promotes tumorigenesis by 39 suppressing VHL expression. Furthermore, biochemical analyses demonstrate 40 that Daam2 associates with VHL and facilitates its ubiquitination and degradation. 41
Together, these studies are the first to define an upstream mechanism regulating 42 VHL suppression in cancer and describe the role of Daam2 in tumorigenesis. suggests that additional regulatory mechanisms oversee VHL dysregulation or 101 inactivation in other malignancies. Indeed recent studies have shown that ID2 102 can interfere with VHL activity in glioma cell lines (Lee et al., 2016) . However, the 103 upstream mechanisms that directly regulate VHL expression and protein turnover 104 in cancer remain undefined. 105
One potential mode of tumor suppressor gene regulation is through 106 developmental mechanisms. Developmental processes directly contribute to all 107 forms of malignancy and are utilized by tumorigenic pathways to maintain cells in 108 an undifferentiated and proliferative state (Jackson et al., 2006; Kesari et al., 109 2005; Stiles and Rowitch, 2008) . Given these established molecular and 110 functional interactions, it stands to reason that expression of tumorigenic 111 pathways may be reciprocally regulated by developmental mechanisms. 112
However, whether such reciprocal regulation of tumor suppressor pathways by 113 developmental factors contributes to tumorigenesis is poorly defined. 114
To investigate the interface between developmental programs and the 115 regulation of tumor suppressor pathways, we used malignant glioma as a model 116 system. As a molecular entry point for these studies, we focused on Daam2, a 117 key developmental regulator that suppresses glial differentiation and also 118 contributes to dorsal patterning in the developing CNS ( we sought to investigate its role in malignancies of the CNS. Towards this we 139 took advantage of the TCGA pan-cancer expression data set (Akbani et al., 2014; 140 Cancer Genome Atlas Research et al., 2013) and evaluated Daam2 expression 141 across a spectrum of 34 malignancies, finding that it's most highly expressed in 142 low-grade glioma (LGG) and glioblastoma multiforme (GBM) ( Figure 1A) . 143
To validate Daam2 expression in LGG and GBM, we used in situ 144 hybridization (ISH) across a cohort of 35 LGG and 40 GBM primary human 145 samples, finding that Daam2 demonstrates heterogeneous expression within 146 each glioma sub-type ( Fig.1B-C) . Notably, the majority of tumors exhibited 147 staining intensity scores that exceeded normal brain samples, indicating that 148
Daam2 expression is elevated within glioma tumors ( Fig ). Finally, we evaluated Daam2 expression in xenograft tumors generated 160 from primary human GBM cell lines, finding that Daam2 is also highly expressed 161 in these human cell line models (Supplemental Figure S1 ). Put together, these 162 studies indicate that Daam2 expression is elevated in both human LGG and 163 GBM and is expressed in the associated model systems. 164 165
Overexpression of Daam2 accelerates glioma tumorigenesis 166
The forging expression analysis in human glioma and associated mouse models 167 led us to examine whether Daam2 contributes to glioma tumorigenesis. To 168 assess its role in glioma, we performed overexpression, gain-of-function (GOF) 169 studies in human GBM cell lines, finding that Daam2 accelerates the rate of cell 170 growth in vitro (Figure 2A-B ). Next, we determined how Daam2 influences 171 anchorage independent growth, via soft agar assay, finding that it also 172 accelerates colony formation ( Figure 2C 
Daam2 suppresses VHL expression 212
Having established that Daam2 functions to promote glioma tumorigenesis, we 213 next sought to uncover the mechanism by which it operates. Previously, we 214 found that Daam2 functions as a positive regulator of Wnt-signaling in the 215 developing CNS (Lee and Deneen, 2012), suggesting that it may also function in 216 this manner in glioma. To evaluate Wnt-activity we used an established Wnt-217 reporter (TOP-FLASH) and found that modulation of Daam2 expression has a 218 modest effect on Wnt activity in glioma cell lines and did not impact Wnt activity 219 in our mouse model of glioma (Supplemental Figure S4) . 220 The RPPA data suggests that Daam2 modulates expression of VHL in glioma. 251
To directly test this hypothesis, we evaluated expression of VHL and its signaling 252 axis in our Daam2-GOF and Daam2-LOF mouse tumor models. Immunostaining 253 for VHL in these models corroborated our RPPA data, where VHL expression 254 was dramatically reduced in Daam2-GOF tumors, and increased in the Daam2 -/-255 tumors ( Figure 4C Given that Daam2 associates with VHL, and expression of VHL protein is 287 negatively correlated with Daam2, we hypothesized that these expression 288 dynamics are the result of Daam2 promoting the degradation of VHL. To test this 289 we co-transfected Daam2 and VHL in 293 cells, and measured the rate of 290 cyclohexamide-mediated degradation, finding that VHL degradation is 291 significantly enhanced in the presence of Daam2 ( Figure 6B , D). The 292 ubiquitination pathway is a central mechanism that oversees protein degradation, 293 Using in vitro systems, we found that in the presence of elevated levels of 296
Daam2, the extent of VHL ubiquitination is substantially increased and levels of 297 VHL protein demonstrate a concomitantly decrease ( Figure 6C ). Together, these 298 mechanistic studies reveal that the underlying biochemical relationship between 299
Daam2 and VHL is mediated by ubiquitin-driven protein degradation. 
New Parallels Between Development and Cancer 353
Our observation that manipulation of Daam2 expression promoted tumorigenesis, 354 but not canonical Wnt signaling, points to the possibility that it functions through a 355
Wnt-independent mechanism. RPPA and bioinformatics approaches revealed 356 that Daam2 expression is inversely correlated with a cohort of genes ( Figure S5 
Regulation of VHL in cancer 387
Mechanistic studies revealed that Daam2 promotes glioma tumorigenesis via 388 suppression of VHL, a classic tumor suppressor that promotes HIF1α 389 degradation and inhibits Akt activity. Importantly, inactivating mutations in VHL 390 are predominately found in ccRCC and are very rare in most other forms of 391 cancer, including glioma. These observations raise the critical question of how 392
HIF1α becomes upregulated in cancers that do not exhibit VHL mutations. Our 393 studies show, for the first time, a regulatory mechanism that operates upstream 394 of VHL in cancer and provides an explanation for how VHL expression is 395 extinguished in tumors that do not have inactivating mutations. Moreover, 396 because Daam2-VHL expression demonstrates a robust, inverse correlation 397 across a spectrum of cancers, this is likely to be a generalized mechanism of 398 VHL suppression in cancer. Interestingly, prior studies in yeast have shown that 399 VHL can be degraded via the Hsp70 and 
In Utero Electroporation (IUE) 436
To generate mouse gliomas, we performed in utero electroporation (IUE). Briefly, 437 the uterine horns were exposed, and DNA combination was injected into the 438 embryonic lateral ventricles along with Fast Green dye as the indicator. Then 
Statistical Analysis 490
One-way ANOVA was used to analyze bioluminescent intensity and BrdU-491 positive cell counts to determine the differences between Ctrl, D2 and D2/VHL 492 groups, followed by Tukey's test to compare between individual groups, which is 493 demarcated by an asterisk in the graphs. Independent t-test was used to analyze 494 the differences in bioluminescent intensity and BrdU-positive cell counts between 495 and Myc-Daam2. Cells were treated with MG132 (10ug/ml) 6 hrs before harvest. 850
Whole-cell lysate were immunoprecipitated with anti-Flag M2 beads then 851 analyzed by western blotting with Flag and HA antibodies. 
